TRxADE HEALTH, Inc. Share Price

Equities

MEDS

US89846A4058

Internet Services

Market Closed - Nasdaq 21:30:00 26/04/2024 BST 5-day change 1st Jan Change
6.31 USD +0.80% Intraday chart for TRxADE HEALTH, Inc. -1.87% +21.43%
Sales 2022 11.45M 916M Sales 2023 8.27M 662M Capitalization 6.48M 519M
Net income 2022 -3M -240M Net income 2023 -17M -1.36B EV / Sales 2022 0.37 x
Net Debt 2022 450K 36.05M Net Debt 2023 6.95M 557M EV / Sales 2023 1.62 x
P/E ratio 2022
-0.98 x
P/E ratio 2023
-0.22 x
Employees 8
Yield 2022 *
-
Yield 2023
-
Free-Float 75.94%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.80%
1 week-1.87%
Current month-38.38%
1 month-32.00%
3 months+43.47%
6 months+3.44%
Current year+21.43%
More quotes
1 week
5.82
Extreme 5.8201
7.08
1 month
5.82
Extreme 5.8201
10.74
Current year
3.69
Extreme 3.69
44.56
1 year
3.69
Extreme 3.69
44.56
3 years
3.69
Extreme 3.69
162.30
5 years
3.69
Extreme 3.69
174.00
10 years
3.69
Extreme 3.69
265.50
More quotes
Managers TitleAgeSince
Founder 49 14/07/05
Chief Executive Officer 53 14/07/05
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 53 14/07/05
Director/Board Member 62 23/08/16
Director/Board Member 66 29/09/22
More insiders
Date Price Change Volume
26/04/24 6.31 +0.80% 14,603
25/04/24 6.26 -2.95% 20,336
24/04/24 6.45 -0.77% 16,467
23/04/24 6.5 -2.40% 9,925
22/04/24 6.66 +3.58% 28,181

Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm

More quotes
TRxADE Health, Inc. provides a technology-enabled health services platform. The Company is focused on digitalizing the retail pharmacy and health services experience by optimizing drug procurement, the prescription journey, access to physicians in the patient’s home and patient engagement in the United States. The Company’s segments include Trxade, Inc., Integra Pharma Solutions, LLC (IPS) and Superlatus. Trxade, Inc. segment provides a web-based pharmaceutical marketplace platform-business to business (B2B) sales. IPS is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. The Superlatus segment holds Sapientia’s intellectual property for advanced food extrusion technology and The Urgent Company, which is a manufacturer of ice cream that is animal product-free, vegan, lactose-free, and made with plant-B2B sales. Its subsidiaries include Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC, Bonum Health, LLC and others.
More about the company